Title: Expression of Alpha-Methylacyl-Coenzyme A Racemase (AMACR) in Colo-Rectal Neoplasms

Authors: Dr S.A.K. Adil, Dr Neha Saroha, Dr Bharathi M

 DOI: https://dx.doi.org/10.18535/jmscr/v8i2.112

Abstract

   

Introduction: Colorectal cancers are gaining importance globally as major cause of morbidity and mortality. AMACR is a dietary enzyme which aids in beta- oxidation of branched chain fatty acids. Hence, its expression in colorectal premalignant lesions and carcinoma suggest possible role in its carcinogenesis.

Aim: To study the expression of AMACR in colorectal neoplasms and its correlation with the histological grade.

Materials and Methods: It is a hospital based retrospective study. 30 blocks were retrieved from tissue samples previously diagnosed as colorectal neoplasms at Mysore Medical College, Mysore during a period of 2 years. AMACR expression was studied by Immunohistochemistry and correlated with histological grade. Mean, frequency and Chi-square tests were used for analysis.

Results: Out of 30 samples with colorectal tumours, 25 were malignant (83.3%) and 5 were benign (16.7%). Age of the study population ranged between 35-75 years. Most of the patients were above 45 years of age (86.6%). Females were affected equally as males representing 50% each. Histological grading revealed 21 cases of well differentiated tumours (84%), 1 case of moderately differentiated tumour (4%) and 3 cases of poorly differentiated tumour (12%). Overall, study showed positive AMACR expression in colorectal neoplasms (63%) and significant correlation between histological grade of carcinoma and AMACR expression.

Conclusion: This study showed increased expression of AMACR in colorectal carcinomas and weakly in adenomas as compared to normal colonic mucosa which suggests its possible role in colorectal carcinogenesis. Loss of AMACR immunostaining in poorly differentiated carcinomas suggests its role in tumour differentiation. AMACR can be used as possible therapeutic agent.

Keywords: Colorectal cancers, Alpha-Methylacyl-Conenzyme A Racemase (AMACR), Immunohistochemistry.

References

  1. Stewart BW, Wild CP, World Cancer Report, Lyon: IARC Press;2014
  2. Jhajj K, Sood N, Malhotra V. Histopathological profile of tumours of Midgut and Hindgut- Five Year Study in Tertiary Care Hospital with review of literature. The International Journal of Pathology.
  3. Ferdinandusse S et al. Subcellular localization and physiological role of alpha-methylacyl-coA racemase. J Lipid Res 2000; 41:1890-1896
  4. Lloyd MD et al- Alphamethyl acyl-CoA Racemase- an ‘obscure’ metabolic enzyme takes centre stage. FEBS J 275: 1089-1102
  5. Lloyd MD et al- Alphamethyl acyl- CoA Racemase( AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S: Prog Lipid Res 52 : 220-230
  6. Ouyang B et al. Alpha methylacyl- CoA racemase spliced variants and their expression in normal and malignant prostate tissue. Urology 77: 249 e1- 249 e7
  7. Emam E et al. Lack of AMACR immunostaining is in aindependent predictor of poor prognosis in colorectal carcinoma.J ClinExp Pathol 2016. 6:3
  8. Jiang Z et al. A dietary enzyme: a-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev 2003;27:422–6
  9.  Lin A, Weiser MR, Klimstra DS, Paty PB, Tang LH, Al-Ahmadie H, et al (2007). Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance. Hum Pathol 38:850–856.
  10.  Marx A et al (2008). AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch 453:243–248
  11.  Nidhi Shukla et al. Expression of Alpha- Methylacyl- Coenzyme A Racemase (AMACR) IN Colorectal neoplasia. Journal of Clinical and Diagnostic Research, 2017 Apr, Vol-11(4): EC35- EC38
  12. Shi X (2007). Alpha-methylacyl-CoA racemase/P504S overexpression in colorectal carcinoma is correlated with tumor differentiation. Appl Immunohistochem Mol Morphol 15:175–180.
  13. Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H. Alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol. 2002 Sep;161(3):841-8.

Corresponding Author

Dr Neha Saroha

Department of Pathology, Mysore Medical College and Research Institute, Mysore, Karnataka